c-MET

Inhibitory Selectivity
Catalog No.Inhibitor Name c-MetOther
A10712Crizotinib
*
ALK
A10996Cabozantinib
***
VEGFR2/KDR,Kit,VEGFR3/FLT4
A10998Foretinib
****
KDR,Tie-2,VEGFR3/FLT4
A10713PHA-665752
**
RON,Flk1,c-Abl
A10869SU11274
**
Flk1,RON,FGFR1
A10839SGX-523
***
A10153BMS-777607
***
Axl,RON,Tyro3
A11087Tivantinib
*
A10493JNJ-38877605
***
A10711PF-04217903
**
A10587MGCD-265
****
RON,VEGFR2,VEGFR1
A11132Capmatinib
****
A11059BMS-754807
**
Insulin Receptor,IGF-1R,TrkB
A10154BMS-794833
***
VEGFR2
A10063AMG-208
**
A11753MK-2461
****
c-Met (Y1235D),c-Met (Y1230C),c-Met (N1100)
A11396Golvatinib
*
VEGFR2
A11055AMG-458
****
VEGFR2
A11257Tepotinib
***
IRAK4,TrkA,Axl
A11150NVP-BVU972
*
A12557Merestinib
***
A15917NPS-1034
*
Axl
A11489MK-8033
****
Ron
A14387Altiratinib
***
TIE-2, VEGFR
A14419Volitinib (Savolitinib, AZD-6094)
A15792BMS-817378
***
VEGFR2

Notes:
1.Hover mouse over " * " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " * " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.



32 Item(s)

per page

Set Descending Direction
Catalog No. Product Name Application Product Information
A10712 SALE

PF-2341066 (Crizotinib)

ALK/ c-Met inhibitor
PF-2341066 (Crizotinib) is an inhibitor of the c-Met kinase and the NPM-ALK. PF-2341066 inhibited cell proliferation in ALK-positive ALCL cells (IC50s=30 nM).
A16257

Glesatinib hydrochloride

MET/Axl inhibitor
Glesatinib hydrochloride is an inhibitor of the MET and Axl receptor tyrosine kinase pathways, which drive tumour growth when altered.
A16256

c-Met inhibitor 2

c-Met inhibitor
c-Met inhibitor 2 is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor.
A12557 SALE

LY2801653 (Merestinib)

c-MET inhibitor
LY2801653 is a potent, orally bioavailable, small-molecule inhibitor of c-MET kinase(Ki= 2 nM).
A15917

NPS-1034

c-Met inhibitor
NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.
A14387

Altiratinib (DCC2701)

c-Met/VEGFR inhibitor
Altiratinib is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro.
A15792

BMS-817378

MET/VEGFR-2 inhibitor
BMS-817378 is a novel prodrug of the dual Met/VEGFR-2 inhibitor BMS-794833.
A15208

PF-04217903 methanesulfonate

c-Met Inhibitor
PF-04217903 methanesulfonate is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant).
A15150 SALE

LY2801653 dihydrochloride

MET inhibitor
LY2801653 dihydrochloride is a potent, orally bioavailable, small-molecule inhibitor of c-MET kinase(Ki= 2 nM).
A11059 SALE

BMS-754807

IGF-1R inhibitor
BMS-754807 is an efficacious, orally active growth factor 1 receptor/insulin receptor family-targeted kinase inhibitor that may act in combination with a wide array of established anticancer agents.
A11087 SALE

ARQ 197

c-Met inhibitor
ARQ-197 is a selective inhibitor of the c-Met receptor tyrosine kinase
A11150 SALE

NVP-BVU972

C-Met inhibitor
NVP-BVU972 is a selective MET inhibitor.
A11132

INCB28060

c-MET Inhibitor
INCB28060, a novel inhibitor of c-MET kinase. INCB28060 exhibits picomolar enzymatic potency and is highly specific for c-MET with more than 10,000-fold selectivity over a large panel of human kinases. This inhibitor potently blocks c-MET phosphorylation and activation of its key downstream effectors in c-MET-dependent tumor cell lines.
A11257 SALE

EMD-1214063

c-Met Inhibitor
EMD-1214063 is an inhibitor of MET tyrosine kinase with potential antineoplastic activity. It binds to MET tyrosine kinase and disrupts MET signal transduction pathways, which may induce apoptosis in tumor cells overexpressing this kinase.
A11753

MK-2461

c-Met Inhibitor
MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
A11396 SALE

E-7050 (Golvatinib)

-
E7050 (also known as golvatinib is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity.
A14419

Volitinib (Savolitinib, AZD-6094)

c-Met inhibitor
Volitinib is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase with potential antineoplastic activity.
A15049

c-Met inhibitor 1

c-Met inhibitor
c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.
A11489

MK-8033

c-Met inhibitor
MK-8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.
A11055 SALE

AMG-458

c-Met inhibitor
AMG-458 is a potent inhibitor of c-Met with an IC50 value of 60nM and displays selectivity against VEGFR2.
A10154 SALE

BMS-794833

c-Met inhibitor
BMS-794833 is a potent ATP competitive inhibitor to Met and VEGFR-2 with IC50 of 1.7 and 15 nmol.
A10996 SALE

XL184 free base (Cabozantinib)

VEGFR inhibitor
XL184 free base (Cabozantinib) is a small molecule designed to inhibit multiple receptor tyrosine kinases, specifically MET and VEGFR2.
A10998 SALE

Foretinib (GSK1363089, XL880)

c-MET inhibitor
Foretinib (GSK1363089), a multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces Anoikis, and impairs ovarian cancer metastasis.
A10869 SALE

SU11274

c-Met inhibitor
SU11274 is a Met tyrosine kinase inhibitor.
A10713 SALE

PHA-665752

c-Met Inhibitor
PHA665752 is a small-molecule inhibitor of c-Met/HGF/SF signaling.
A10839 SALE

SGX-523

c-Met Inhibitor
SGX-523 is an orally bioavailable small molecule, specifically binds to c-Met protein, or HGFR, preventing binding of HGF and disrupting the MET signaling pathway.
A10493 SALE

JNJ-38877605

c-Met inhibitor
c-Met inhibitor JNJ-38877605 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways.
A10153 SALE

BMS-777607

c-Met inhibitor
BMS-777607 is a MET tyrosine kinase inhibitor that binds to c-Met protein, or HGFR, preventing binding of HGF and disrupting the MET signaling pathway.
A10587

MGCD-265 (Glesatinib)

c-Met inhibitor
MGCD265 is a multitargeted tyrosine kinase inhibitor that binds to and inhibits the phosphorylation of several RTKs, including the c-Met receptor (HGFR); the Tek/Tie-2 receptor; VEGFR types 1, 2, and 3; and MST1R.
A10711 SALE

PF-04217903

c-Met Inhibitor
PF-04217903 is a novel c-Met/hepatocyte growth factor receptor tyrosine kinase inhibitors.
A10063

AMG 208

c-Met Inhibitor
AMG 208 is a novel c-Met inhibitor that inhibits the ligand-dependent and ligand-independent activation of c-Met, inhibiting its tyrosine kinase activity.
A16400

AMG 337

MET inhibitor
AMG 337 is an oral, small molecule, ATP-competitive, highly selective inhibitor of the MET receptor.

32 Item(s)

per page

Set Descending Direction